| Source of record | UK Co-ordinating Committee on Cancer Research (UKCCCR) |
| Serial number at source | MRC PRV |
| Title of trial | Medical Research Council Polycythaemia Trial |
| Disease or condition | Plasma cell neoplasms |
| Current status of trial | Closed |
| Objectives | To compare the treatment of polycythaemia rubra vera (PRV) with either radiophosphorous (32P), busulphan, or venesection with respect to:
1. Duration of survival
2. Incidence of acute leukaemia and myelosclerosis
3. Chromosomal abnormalities occurring before and during treatment |
| Design/methodology | 1. Randomisation 1:1:1
2. The physician must decide for each patient between a three way, two way (busulphan versus 32P), or one way (venesection for as long as possible followed by the two way randomisation) randomisation. |
| Eligibility criteria | 1. Definite diagnosis of polycythaemia made by appropriate clinical and laboratory evaluation.
2. Patients not previously treated with 32p, busulphan or any other cytotoxic.
3. No life-threatening intercurrent disease. |
| Sample size | 400 |
| Randomised interventions | 1. Arm A:
Radiophosphorous, 5mCi in single dose plus venesection if indicated.
2. Arm B:.
Busulphan daily for twenty-eight days plus venesection if indicated.
3. Arm C:
Venesection. |
| Sponsor | Medical Research Council |
| Contact details | UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
LONDON NW1 2DA
Tel: +44 (0) 20 7670 4723
Fax: +44 (0) 20 7670 4818
|
| Further information | Further information about this trial may be obtained from UKCCCR Register's own website, which contains full trial reports. |
| General information | Please visit the UKCCCR Register website for further general information. |
| Date live in mRCT | 01 April 2007 |
